Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 20, 1997

View Archived Issues

Avax evaluates its ovarian cancer vaccine in phase II

Promising preliminary phase II data reported for VX-478/141W94

PharmaPrint and AHP to collaborate on herbal products

Clinical results reported for 546C88 in septic shock

ImClone and CombiChem enter alliance for drug discovery in oncology

Schering-Plough: Q3 1997 highlights

Synthelabo: Q3 1997 highlights

Prodrugs of selective COX-2 inhibitors

Warner-Lambert prepares new cyclic amino acids related to gabapentin

BASF prepares anti-hTNF-alpha antibodies

Two large trials support use of alteplase accelerated infusion for acute MI

Shire files IND for new formulation of aciclovir

Peptech and Allergan terminate collaboration on GMDP

Cefluprenam: basic and clinical research on new injectable cephalosporin

Effects of 5-HT, TxA2 and their antagonists on restenosis

Andrx's Diltia XT approved and launched in U.S.

Alpharma will distribute PerioGlas in key European markets

FDA approves RPR's Nasacort for pediatric use

New cell therapy company to be formed by VIMRx and Baxter

Peptech reaches phase I goals for antagonist G; exercises license option

Products under development at Meiji Seika

Advisory panel to the FDA unanimously recommends PDL's Zenapax

Toyama to begin U.S. development of Alzheimer's drug

Peripheral and Central Nervous System Drugs Advisory Committee meets next month

U.S. testing of Toyama antiarthritic to begin soon

Anti-Infective Drugs Advisory Committee to discuss three NDAs

Viragen considers genital herpes as possible target for Omniferon

Australian government awards Cortecs grant for otitis media research

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...